共 50 条
- [21] Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)Zong HongZhong QianZhao RuihuaJin ShuilingZhou ChuangZhang XiaojianShi JianxiangQiao ShishiHan JinmingJiang Miao
- [22] A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers.JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 340S - 340SGebbia, NVerderame, FDi Leo, RSantangelo, DCicero, GValerio, MRArcara, CBadalamenti, GFulfaro, FCarreca, I
- [23] Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract CarcinomaONCOLOGIST, 2023, 28 (10): : E917 - E966Tella, Sri HarshaFoster, NathanQian, ShiNguyen, TranBorad, Mitesh J.McWilliams, Robert R.Alberts, Steven R.Ma, Wen WeeChakrabarti, SaktiFruth, BriantWessling, JaclynnHartgers, MindyWashburn, LeslieFernandez-Zapico, Martin E.Hogenson, Tara L.Pitot, HenryJin, ZhaohuiMahipal, Amit
- [24] A phase Ib trial of cabozantinib in combination with durvalumab (MEDI4736) in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies (CAMILLA).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)Saeed, AnwaarKoestler, DevinWilliamson, Stephen K.Baranda, Joaquina CelebreSun, WeijingAl-Rajabi, Raed Moh'd TaiseerKasi, AnupAl-Kasspooles, Mazin FrancisSubramaniam, DharmalingamAnant, Shrikant
- [25] Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) plus radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Reardon, David A.Kaley, Thomas JosephDietrich, JorgClarke, Jennifer LeighDunn, GavinLim, MichaelCloughesy, Timothy FrancisGan, Hui KongPark, Andrew J.Schwarzenberger, PaulRicciardi, ToniMacri, Mary J.Ryan, AileenVenhaus, Ralph Rudolph
- [26] A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Kim, Richard D.Kim, Dae WonAlese, Olatunji B.Li, DanengShah, NealSchell, Michael J.Zhou, Jun MinChung, Vincent
- [27] MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Leventakos, KonstantinosDimou, AnastasiosFoster, Nathan R.Flickinger, Lynn M.Tella, Sri HarshaMolina, Julian R.Mansfield, Aaron ScottMarks, RandolphSchwecke, Anna J.Hocum, CraigMoffett, Jenesse NicolePotter, AshleyAdjei, Alex A.
- [28] Regorafenib in Patients with Antiangiogenic-Naive and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb TrialONCOLOGIST, 2019, 24 (09): : 1180 - 1187Riechelmann, Rachel P.Leite, Luiz S.Bariani, Giovanni M.Glasberg, JoaoRivelli, Thomas G.da Fonseca, Leonardo GomesNebuloni, Daniela R.Braghiroli, Maria, IQueiroz, Marcelo A.Isejima, Alice M.Kappeler, ChristianKikuchi, LucianaHoff, Paulo M.
- [29] Phase II study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naive patients with recurrent GBMCANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)Reardon, David A.Kaley, ThomasDietrich, JorgLim, MichaelDunn, Gavin P.Gan, Hui K.Cloughesy, TimothyClarke, Jennifer L.Park, AndrewMacri, MaryRyan, AileenRicciardi, ToniReddy, VijayVenhaus, Ralph
- [30] A phase II trial with safety run-in of neoadjuvant therapy with an aromatase inhibitor in combination with durvalumab (MEDI4736) in postmenopausal patients with hormone-receptor-positive (HR plus ) breast cancerCANCER RESEARCH, 2021, 81 (04)Khong, Hung T.Goodridge, Dawn N.Khakpour, NazaninLee, M. CatherineLaronga, ChristineArmaghani, Avan J.Soyano-Muller, Aixa E.Han, HyoSoliman, HatemCosta, RicardoLoftus, LorettaHoover, Susan J.Kiluk, John V.Jameel, ZenaCzerniecki, Brian J.